CEA, Institut des Maladies Emergentes et des Therapies Innovantes (IMETI), Service de Recherche en Hemato-Immunologie (SRHI), Hopital Saint-Louis, Paris, France.
Stem Cells. 2013 Nov;31(11):2296-303. doi: 10.1002/stem.1494.
Both human leukocyte antigen G (HLA-G) and multipotential mesenchymal stem/stromal cells (MSCs) exhibit immunomodulatory functions. In allogeneic tranplantation, the risks of acute and chronic rejection are still high despite improvement in immunosuppressive treatments, and the induction of a state of tolerance to alloantigens is not achieved. Immunomodulatory properties of MSCs and HLA-G in human allogeneic tranplantation to induce tolerance appears attractive and promising. Interestingly, we and others have demonstrated that MSCs can express HLA-G. In this review, we focus on the expression of HLA-G by MSCs and discuss how to ensure and improve the immunomodulatory properties of MSCs by selectively targeting MSCs expressing HLA-G (MSCs(HLA-G+)). We also discuss the possible uses of MSCs(HLA-G+) for therapeutic purposes, notably, to overcome acute and chronic immune rejection in solid-organ allogeneic transplantation in humans. Since MSCs are phenotypically and functionally heterogeneous, it is of primary interest to have specific markers ensuring that they have strong immunosuppressive potential and HLA-G may be a valuable candidate.
人类白细胞抗原 G（HLA-G）和多能间充质干细胞（MSCs）都具有免疫调节功能。尽管免疫抑制治疗有所改善，但同种异体移植仍存在急性和慢性排斥的风险，无法实现对同种异体抗原的耐受状态。MSCs 和 HLA-G 在人类同种异体移植中诱导免疫耐受的免疫调节特性似乎具有吸引力和前景。有趣的是，我们和其他人已经证明 MSCs 可以表达 HLA-G。在这篇综述中，我们重点关注 MSCs 表达 HLA-G 的情况，并讨论如何通过选择性靶向表达 HLA-G 的 MSCs（MSCs（HLA-G+））来确保和改善 MSCs 的免疫调节特性。我们还讨论了 MSCs（HLA-G+）在治疗用途中的可能用途，特别是在人类实体器官同种异体移植中克服急性和慢性免疫排斥。由于 MSCs 在表型和功能上具有异质性，因此具有确保其具有强大免疫抑制潜力的特异性标志物是首要关注的问题，而 HLA-G 可能是一个有价值的候选标志物。
